A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Hong Suk | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Chang, Heung Moon | - |
dc.contributor.author | Ryu, Min Hee | - |
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Hong, Dae Sik | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.contributor.author | Lee, Kyoung Eun | - |
dc.contributor.author | Kim, Si Young | - |
dc.date.accessioned | 2021-09-09T03:54:47Z | - |
dc.date.available | 2021-09-09T03:54:47Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2008-10 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/122621 | - |
dc.description.abstract | Purpose This open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Patients and methods We enrolled 63 patients who received capecitabine 830 mg/m(2) orally twice daily on days 1-21 plus gemcitabine 1000 mg/m(2) as a 30-min infusion on days 1, 8 and 15 every 4 weeks for up to six cycles. Results A total of 14 patients had partial responses giving an overall response rate of 22% (95% confidence interval [CI] 13-34%) in the intent-to-treat population. The median time to progression and overall survival were 3.9 months (95% CI 3.5-5.7) and 7.5 months (95% CI 5.0-10.0), respectively, and 1-year survival rate was 27.1% in the intent-to-treat population. Capecitabine plus gemcitabine was well tolerated. Grade 3 hematological adverse events were neutropenia (21%) and thrombocytopenia (2%); the only grade 4 hematological events were anemia (2%) and neutropenia (6%). Non-hematological adverse events were mainly gastrointestinal events and hand-foot syndrome, which affected 16% of patients. Grade 3/4 non-hematological events were infrequent. Conclusion The combination of capecitabine plus gemcitabine appears to be active and well tolerated as first-line treatment in patients with advanced/metastatic pancreatic cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | COLORECTAL-CANCER | - |
dc.subject | ORAL CAPECITABINE | - |
dc.subject | COMBINATION | - |
dc.subject | THERAPY | - |
dc.subject | TRIAL | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | INFUSION | - |
dc.subject | DESIGN | - |
dc.title | A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1007/s00280-007-0661-y | - |
dc.identifier.scopusid | 2-s2.0-49749126800 | - |
dc.identifier.wosid | 000258527900003 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.62, no.5, pp.763 - 768 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 62 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 763 | - |
dc.citation.endPage | 768 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | ORAL CAPECITABINE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | INFUSION | - |
dc.subject.keywordPlus | DESIGN | - |
dc.subject.keywordAuthor | pancreatic cancer | - |
dc.subject.keywordAuthor | capecitabine | - |
dc.subject.keywordAuthor | gemcitabine | - |
dc.subject.keywordAuthor | chemotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.